ASP Isotopes Inc.

ASP Isotopes Inc. is an advanced materials company focused on developing a differentiated isotope enrichment platform to enhance global supply chain access to critical materials for nuclear medicine, next-generation semiconductors, and nuclear energy. The company utilizes proprietary Aerodynamic Separation Process (ASP technology) and Quantum Enrichment (QE technology) for isotope production ¹. In January 2026, the company acquired Renergen, South Africa’s leading onshore natural gas explorer and the first integrated producer of liquid helium and LNG ².

The core business model revolves around generating revenue through the production and commercialization of enriched isotopes and, following the Renergen acquisition, the production and sale of liquid helium and LNG. The company's initial focus for its isotope enrichment platform is on enriched Carbon-14 (C-14), Silicon-28 (Si-28), and Ytterbium-176 (Yb-176) ³. The company also entered the downstream medical isotope production and distribution market through a 51% ownership stake in PET Labs Pharmaceuticals Proprietary Limited (PET Labs) ⁴ and the acquisition of East Coast Nuclear Pharmacy (ECNP) ⁵. Furthermore, QLE, a subsidiary, acquired a controlling interest in Skyline Builders Group Holding Limited (Skyline) in August 2025, which primarily conducts construction activities in Hong Kong ⁶.

The company's operations are segmented into three categories: Nuclear Fuels, Specialist Isotopes and Related Services, and Construction Services. The Nuclear Fuels segment focuses on research and development of technologies for producing High-Assay Low-Enriched Uranium (HALEU) and Lithium-6 for advanced nuclear fuels ⁷. The Specialist Isotopes and Related Services segment concentrates on research and development for separating high-value, low-volume isotopes like C-14, Si-28, and Yb-176 for specialized markets such as pharmaceuticals, agrochemicals, nuclear medical imaging, and semiconductors, and includes PET Labs ⁸. The Construction Services segment, acquired through Skyline, provides public civil engineering services in Hong Kong, including road and drainage works ⁹.

For the fiscal year ended December 31, 2025, the company reported a net loss of $159.8 million ¹⁰, compared to a net loss of $32.4 million for the year ended December 31, 2024 ¹¹. As of December 31, 2025, the company had an accumulated deficit of $231.3 million ¹². Cash and cash equivalents were approximately $285.6 million ¹³, and short-term investments were approximately $47.7 million ¹⁴. The company currently has no sales attributable to enriched isotopes ¹⁵.

During the first half of 2025, the company commenced commercial production of enriched isotopes at both ASP enrichment facilities in Pretoria, South Africa ¹⁶. The first facility is designed for light isotopes such as C-14 and C-12, while the second, larger facility has the potential to enrich kilogram quantities of heavier isotopes including Si-28 ¹⁷. The third enrichment facility, a QE technology plant, completed its commissioning phase and is producing commercial samples of highly enriched Yb-176 ¹⁸. In August 2025, QLE acquired a controlling interest in Skyline ¹⁹. In January 2026, ASP Isotopes acquired Renergen ²⁰. In October 2025, the company completed the acquisition of East Coast Nuclear Pharmacy for a total purchase consideration of $2.5 million, with $2.0 million paid upfront in cash and the remaining $0.5 million deferred through notes payable due by June 30, 2026 ²¹. In November 2025, Skyline acquired a 13.09% ownership of Reemag LLC for a cash purchase price of $3.0 million ²². On October 31, 2025, Skyline subscribed for an approximate 20% membership interest in a critical minerals space company for $20.0 million ²³.

The company is targeting initial commercial shipments of enriched C-14 in mid-2026 ²⁴ and initial commercial shipments of enriched Si-28 during the second quarter of 2026 ²⁵. Initial commercial shipments of Yb-176 are targeted for mid-2026 or the third quarter of 2026 ²⁶. The company plans to request drawdowns on the TerraPower loan, totaling $22.0 million, beginning in the third quarter of 2026 ²⁷. The total loan amount is inclusive of a 10% original issue discount on each disbursement and carries a fixed interest rate of 10% per annum, with aggregate loan disbursements of $20.0 million ²⁸. Principal and interest payments will be made in 60 equal installments beginning in November 2027 ²⁹.

A major growth area is the production of C-14, which has historically been solely supplied by Russia, for use in pharmaceuticals and agrochemicals ³⁰. The company has received an initial supply of feedstock from a Canadian customer and has begun C-14 enrichment, with a tolling agreement that includes a minimum "take or pay" amount of approximately $2.5 million per year, supported by a bank letter of guarantee ³¹. Another growth area is Si-28 for advanced semiconductors and quantum computing, with the ASP technology being ideally suited for enriching low molecular mass gases like silane ³². The company has entered into three purchase agreements for highly enriched Si-28 with a U.S. semiconductor company, a global industrial gas company, and a large U.S. buyer ³³. Enriched Yb-176, produced using QE technology, is another growth area, as it can be irradiated to produce Lutetium-177 for radiotherapeutics in oncology ³⁴. The company believes it has obtained all necessary licenses in South Africa for the commercial development of this product ³⁵.

The company also intends to pursue opportunities to acquire assets in the critical materials supply chain through QLE ³⁶. QLE is pursuing an initiative to apply enrichment technologies to Uranium-235 (U-235) enrichment in South Africa, with the belief that the U-235 produced could be commercialized as a nuclear fuel component for HALEU-fueled small modular reactors ³⁷. The company has entered into a term loan agreement with TerraPower, LLC to support the construction of a new uranium enrichment facility at Pelindaba, South Africa, and supply agreements for future HALEU supply to TerraPower ³⁸. The long-term supply agreement is a 10-year agreement for up to 150 metric tons of HALEU, commencing in 2028 through the end of 2037 ³⁹. QLE South Africa has also entered into a Pre-Implementation Services Contract Agreement with The South African Nuclear Energy Corporation (Necsa) for facilities, infrastructure, utilities, and services related to the enrichment facility ⁴⁰. In March 2026, QLE UK entered into an agreement with the University of Bristol for the design of a lithium laser research facility in the UK, with an estimated four-month initial phase for design and feasibility study ⁴¹.

The Renergen acquisition in January 2026 introduces the Virginia Gas Project, which includes the liquefaction of natural gas into LNG, separation of helium from natural gas, and further liquefaction into 99.999% pure liquid helium ⁴². Renergen's average helium concentration exceeds 3.0%, which is well above typical conventional natural gas reservoirs ⁴³. The LNG will be sold domestically in South Africa, and helium will be sold globally, addressing energy and helium supply shortages ⁴⁴. The Production Right for the Virginia Gas Project is valid through September 20, 2042, and is renewable for an additional 30-year period ⁴⁵. The company submitted an application to incorporate its Exploration Rights into its Production Right, which was authorized on May 9, 2025, with an ongoing appeal process expected to be resolved in 2027 ⁴⁶. Phase 1 of the Virginia Gas Project has commenced commercial LNG operations, and drilling for wells to reach the required cumulative nameplate flow rate is complete, with gas gathering and tie-in connections ongoing ⁴⁷.

The estimated build cost to complete construction of Phase 2 of the Virginia Gas Project is approximately $1.16 billion, including borrowing costs and general corporate costs during construction ⁴⁸. The company has received conditional approval from the U.S. International Development Finance Corporation (DFC) for up to $500 million of senior secured debt for Phase 2, and the Standard Bank of South Africa has conditionally approved an additional $250 million of senior secured debt funding ⁴⁹. Renergen is required to contribute sufficient equity such that Tetra4's debt to equity ratio will not exceed 65% to 35% ⁵⁰.

The company faces numerous material risks, including significant net losses since inception and a limited operating history, making future performance difficult to evaluate ⁵¹. The business relies heavily on the successful commercialization of future isotopes, which may not achieve market acceptance or regulatory approval, and is dependent on a few large customers, making it vulnerable to reduced business ⁵². Substantial additional capital will be required to finance operations, including the estimated $1.16 billion ⁵³ for Phase 2 of the Virginia Gas Project, and failure to obtain this funding could delay or terminate development efforts ⁵⁴. The company is exposed to credit counterparty risk, particularly with cash balances exceeding FDIC insurance limits at U.S. financial institutions and non-U.S. banking counterparties potentially lacking standard protections ⁵⁵. Regulatory compliance is a significant risk, as the company's isotope enrichment technology may be classified as "dual use" and subject to strict limitations on public disclosure or export, and its South African Exploration Rights and Production Right could be altered, suspended, or canceled ⁵⁶. Operations in South Africa are vulnerable to economic, political, or social instability, including power outages, which could disrupt development activities and negatively impact profits ⁵⁷. The company's intellectual property is not protected by patents or formal copyright registration, relying instead on trade secrets and non-disclosure agreements, which increases the risk of replication or unauthorized disclosure by competitors ⁵⁸. There is also a risk of infringing third-party intellectual property rights, leading to costly litigation or the need for expensive licenses ⁵⁹. The company is highly dependent on its senior management team and the ability to attract and retain qualified personnel, and difficulties in managing organizational expansion could disrupt operations ⁶⁰. International operations expose the company to foreign currency fluctuations, differing legal and regulatory requirements, and geopolitical risks, including the ongoing military conflicts in Russia-Ukraine and USA-Israel-Iran, which could adversely affect global energy markets and the company's business ⁶¹. The company's tangible assets may be subject to defects in title, and disputes with landowners regarding access and servitude agreements could cause delays and additional costs ⁶². Poor general economic, business, or political conditions, including high inflation in South Africa, may adversely affect results of operations, liquidity, and financial condition ⁶³. Unplanned stoppages, operational interruptions, and accidents could adversely affect performance, and the company's insurance coverage may not adequately satisfy all potential claims ⁶⁴. The company has identified a material weakness in its internal control over financial reporting related to a lack of formal control documentation, consistent execution of control procedures, and insufficient personnel in finance and accounting, as well as logical security and privileged access in information technology ⁶⁵. Failure to remediate this weakness could adversely affect investor confidence and stock value ⁶⁶. The company has been subject to securities class action litigation, and future litigation could result in substantial costs and diversion of management resources ⁶⁷. QLE's future success depends on target markets for advanced nuclear fuels that are not yet established, and competition from existing or new companies could lead to downward pressure on prices and loss of market share ⁶⁸. The HALEU supply agreements with TerraPower are terminable for convenience, meaning QLE may never realize revenue from them ⁶⁹. The expansion of the Virginia Gas Project into Phase 2 faces risks of unforeseen difficulties, delays, and costs, with the estimated $1.16 billion ⁷⁰ build cost based on assumptions that may be inaccurate ⁷¹. There is no assurance that the necessary financing for Phase 2, including conditional DFC and Standard Bank of South Africa debt, will be obtained on acceptable terms or at all ⁷².

Management's message to shareholders emphasizes the company's dedication to developing a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials for nuclear medicine, next-generation semiconductors, and nuclear energy, utilizing proprietary ASP and QE technologies. They highlight the recent commencement of commercial production at ASP enrichment facilities in Pretoria, South Africa, during the first half of 2025, with initial commercial shipments of enriched C-14 targeted for mid-2026 ⁷³, enriched Si-28 during the second quarter of 2026 ⁷⁴, and Yb-176 in mid-2026 or the third quarter of 2026 ⁷⁵. A key strategic priority is the pursuit of uranium enrichment through QLE, with conditional commitments from TerraPower for a term loan totaling $22.0 million ⁷⁶ to partially fund a new uranium enrichment facility in South Africa, and supply agreements for up to 150 metric tons of HALEU ⁷⁷ commencing in 2028 through the end of 2037 ⁷⁸. The acquisition of Renergen in January 2026 is also a significant strategic move, integrating South Africa's leading onshore natural gas explorer and producer of liquid helium and LNG into the company's portfolio.